Regency Capital Management Inc. DE Sells 97,744 Shares of Aura Biosciences, Inc. (NASDAQ:AURA)

Regency Capital Management Inc. DE lowered its holdings in Aura Biosciences, Inc. (NASDAQ:AURA) by 12.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 667,311 shares of the company’s stock after selling 97,744 shares during the quarter. Aura Biosciences comprises approximately 3.3% of Regency Capital Management Inc. DE’s investment portfolio, making the stock its 13th largest holding. Regency Capital Management Inc. DE owned about 1.35% of Aura Biosciences worth $5,946,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of AURA. American Century Companies Inc. acquired a new stake in Aura Biosciences in the 2nd quarter valued at $119,000. American International Group Inc. boosted its holdings in Aura Biosciences by 27.4% during the 1st quarter. American International Group Inc. now owns 17,579 shares of the company’s stock worth $138,000 after acquiring an additional 3,782 shares during the last quarter. Virtu Financial LLC purchased a new position in Aura Biosciences during the 1st quarter worth $144,000. Trexquant Investment LP boosted its holdings in Aura Biosciences by 64.5% during the 4th quarter. Trexquant Investment LP now owns 17,362 shares of the company’s stock worth $154,000 after acquiring an additional 6,809 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new position in Aura Biosciences during the 3rd quarter worth $169,000. Institutional investors and hedge funds own 96.75% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on AURA shares. Lifesci Capital raised shares of Aura Biosciences to a “strong-buy” rating in a report on Monday, September 9th. JMP Securities lifted their price objective on shares of Aura Biosciences from $19.00 to $23.00 and gave the stock a “market outperform” rating in a report on Friday, September 13th. Evercore ISI raised shares of Aura Biosciences to a “strong-buy” rating in a report on Monday, September 16th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $21.00 price objective on shares of Aura Biosciences in a report on Friday, September 13th. Three analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Aura Biosciences currently has an average rating of “Buy” and a consensus price target of $21.67.

Aura Biosciences Trading Down 0.1 %

Shares of NASDAQ:AURA traded down $0.01 during midday trading on Friday, reaching $8.72. The company had a trading volume of 63,915 shares, compared to its average volume of 171,709. The company’s 50 day moving average price is $8.64 and its 200 day moving average price is $7.94. The stock has a market cap of $432.01 million, a P/E ratio of -4.65 and a beta of 0.37. Aura Biosciences, Inc. has a 52-week low of $5.99 and a 52-week high of $12.35.

Aura Biosciences (NASDAQ:AURA) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.04. Research analysts forecast that Aura Biosciences, Inc. will post -1.7 EPS for the current fiscal year.

Aura Biosciences Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.